Aaron Edwards
@aedwards02
Co-Founder/CEO @KiraGenBio | MS/MBA @HarvardHBS | Past CAR-T editing @beamtx & @bluebirdbio.
In GBM, where survival is measured in months, remission beyond 2 years is extraordinary. CAR-T @ASCO updates: 👉 @BryanDChoi @MGBneurosurgery 👉 @DrORourke2 @StephenBagleyMD @PennCancer show tumor shrinkage, extended survival, and real signs of durability. Let's Build!
A hidden gem in the budget bill: It fixes the Inflation Reduction Act’s disincentive to develop treatments for rare diseases. wsj.com/opinion/orphan… via @WSJopinion
Join us today for #GlioblastomaAwarenessDay to learn about one of the deadliest pediatric brain tumors—glioblastoma multiforme. This aggressive tumor is often resistant to current treatments, making it vital to raise awareness about its impact on families.
What if “sexy science” could save the world? 😎🔬 It hooked me early—front-row seat to mRNA vaccine breakthroughs via @DARPA & @ragoninstitute. Pt 2 of my chat w/ @Jon_Chee dives into that wild ride, the cold email that sparked it all, & chasing passion that lights you up! 🔥
"I had the opportunity to go on what I thought was the coolest thing since sliced bread, a DARPA project. And that [project] was mRNA vaccines. So my claim to fame was getting a taste at what eventually translated into something that saved the world during COVID. That was my…
"Continuing to ask questions and not assuming someone else is doing a job... lets me continue to ask the questions and hopefully ask the right ones eventually to continue to grow."
Excited to share that @KiraGenBio has been selected to join the inaugural AI BioHub from @c10labs & @LabCentral! We’re building multiplex-edited CAR-T therapies guided by AI—and thrilled to be part of a cohort pushing the future of #TechBio forward. 🔗labcentral.org/events-and-med…
Just dropped! 🎉 Had a blast on @SheekeyScience The Sheekey Science Show with @EleanorSheekey discussing how @KiraGenBio is using gene editing + ML‑powered CAR‑T to tackle deadly solid tumors like GBM. Dive into our origin story and vision! 🧬🎧 Link: youtu.be/OMOCa8DmJxQ
Join us on August 6, 2025, at 1 PM CT for Molecular Therapy Presents: Advancements in pediatric cancer therapy, featuring talks on cell therapy for AML and rare pediatric cancer. Register here: dlvr.it/TLrlqw
Breakthroughs in #glioblastoma treatment aren’t optional — they’re urgent. For patients and families, every delay is a life not lived fully.
For the thousands of people diagnosed with #glioblastoma each year — and for everyone who loves them — breakthroughs simply can’t wait.
Honored to be featured in Part 1 of 4 of my conversation with @jonchee_excedr on @Excedr’s The Biotech Startups Podcast. 🌈🧬 We talk curiosity, queerness/otherness, and how Ms. Frizzle (+ real ones from my Kentucky roots) helped shape my path to founding @KiraGenBio.
"What you don't want to do is just as important as learning what you might want to do when you grow up."
This work nails a key TME hurdle @KiraGenBio doesn’t yet tackle: physical barriers. Imagine a tri-CAR—two tumor antigen binders to prevent escape, a third for ECM to aid infiltration, plus our TME-Guards to prevent suppression for durable function. Let’s build it!
Honoured to be part of the incredible team Jenkins at WEHI, The Brain Cancer Centre and team Hulett at LIMS. Proud to help reframe the tumour microenvironment as something we can outsmart! Loved working with all of you, please have a read! #braincancer #CARTCells #ECM
Welcome to the stage, regulatory NK cells! Cool. Do we call these NKRegs? RegNKs?
#ScienceSaturday ❓Why don’t some immune cells perform well in the fight against #cancer? ➡️ In this study, No-Joon Song et al. found that certain natural killer (NK) cells inside tumors can actually block the growth of the CD8+ T cells we need to fight cancer, while allowing…
Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion statnews.com/2025/06/17/eli… via @statnews
Thursday morning, I had the privilege of speaking with the Muldoon family, whose 10-month-old son, baby KJ, was discharged Wednesday from @ChildrensPhila. Baby KJ was diagnosed with a rare urea cycle disorder and received a first-of-its-kind personalized CRISPR gene-editing…
New in @NatureMedicine, our researchers have found that a dual-target CAR T-cell therapy approach shows promise for slowing tumor growth in glioblastoma. @StephenBagleyMD @DrORourke2 @PennCancer @PennMedicine ➡️ spr.ly/6011NCoGT
#ASCO25 Updates on Claudin18.2 CART: “Globally, this is the first ever randomized controlled trial of a CAR T-cell therapy in solid tumors to achieve superiority”
First trial of CAR-T cell ca tx for solid tumor response: @ASCO #ASCO25 Satricabtagene autoleucel (satri-cel)/CT041 demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit in patients with previously treated,…
@StephenBagleyMD will present our completed trial in recurrent #Glioblastoma at #ASCO25 tomorrow AM and our full paper will be online at @NatureMedicine in the AM Very exciting data with our partners at @KitePharma #cureGBM
#ASCO25 Tune into the “Turning ‘Cold’ Tumors ‘Hot’” Clinical Science Symposium tomorrow morning to hear more from @StephenBagleyMD on CAR T cell therapy for recurrent #glioblastoma. Abstract 102. @PennNSG @DrORourke2